Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Non-Current Assets (2016 - 2025)

CytomX Therapeutics' Other Non-Current Assets history spans 12 years, with the latest figure at $31000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 96.98% year-over-year to $31000.0; the TTM value through Dec 2025 reached $31000.0, down 96.98%, while the annual FY2025 figure was $31000.0, 96.98% down from the prior year.
  • Other Non-Current Assets reached $31000.0 in Q4 2025 per CTMX's latest filing, down from $1.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.0 million in Q1 2025 to a low of $27000.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $637700.0, with a median of $917000.0 recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: crashed 97.06% in 2022, then surged 1185.0% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $917000.0 in 2021, then plummeted by 97.06% to $27000.0 in 2022, then surged by 207.41% to $83000.0 in 2023, then surged by 1137.35% to $1.0 million in 2024, then crashed by 96.98% to $31000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Other Non-Current Assets are $31000.0 (Q4 2025), $1.0 million (Q3 2025), and $56000.0 (Q2 2025).